Patient Guide: Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 111 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06042478
Status: ACTIVE_NOT_RECRUITING
Condition: Chronic Spontaneous Urticaria
Phase: PHASE3

Find a Study Location Near You

This study is available at 111 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • CABA, Buenos Aires
  • Rosario, Santa Fe Province
  • Bahía Blanca,
  • • And 108 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily